Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients

Int J Clin Pharm. 2015 Aug;37(4):555-8. doi: 10.1007/s11096-015-0077-4. Epub 2015 May 23.

Abstract

Case description The use of i.v. colistin reappeared recently for the treatment of multidrug-resistant Gram negative organisms in the intensive care and cystic fibrosis (CF) setting. According to the latest pharmacokinetic data, a loading dose and high antibiotic doses are given. Two cases of adverse events (paraesthesias, bad taste) were observed immediately after the start of infusion of a high dose of i.v. colistin in adult CF patients at the Ghent University Hospital. Conclusion Recommendations for optimal administration of i.v. colistin in adult CF patients are scarce. This article highlights the importance of mode of administration to avoid toxicity and relates it to recent pharmacokinetic/-dynamic literature.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Colistin / administration & dosage
  • Colistin / adverse effects
  • Colistin / therapeutic use*
  • Cystic Fibrosis / complications*
  • Female
  • Gram-Negative Bacterial Infections / complications
  • Gram-Negative Bacterial Infections / drug therapy*
  • Humans
  • Infusions, Intravenous
  • Male
  • Paresthesia / chemically induced

Substances

  • Anti-Bacterial Agents
  • Colistin